药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Tiludronic acid
Edrecolomab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Edrecolomab.
Tiludronic acid
Bezlotoxumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Bezlotoxumab.
Tiludronic acid
Olokizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Olokizumab.
Tiludronic acid
Tregalizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tregalizumab.
Tiludronic acid
Racotumomab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Racotumomab.
Tiludronic acid
Namilumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Namilumab.
Tiludronic acid
Rovalpituzumab Tesirine
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Rovalpituzumab Tesirine.
Tiludronic acid
Robatumumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Robatumumab.
Tiludronic acid
Milatuzumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Milatuzumab.
Tiludronic acid
Bimekizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Bimekizumab.
Tiludronic acid
Sacituzumab govitecan
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Sacituzumab govitecan.
Tiludronic acid
Ozanezumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ozanezumab.
Tiludronic acid
Clazakizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Clazakizumab.
Tiludronic acid
Amatuximab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Amatuximab.
Tiludronic acid
Rontalizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Rontalizumab.
Tiludronic acid
Depatuxizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Depatuxizumab.
Tiludronic acid
Concizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Concizumab.
Tiludronic acid
Crotedumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Crotedumab.
Tiludronic acid
Naptumomab Estafenatox
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Naptumomab Estafenatox.
Tiludronic acid
Ecromeximab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ecromeximab.